Philadelphia, PA— Live from EFP ‘18: This afternoon, a panel of 5 patients, advocates and pharma-patient connectors engaged in a discussion titled, “Where is the trust? Strengthen relationships through partnerships and collaborations.” The conversation held great relevance for our industry, but few quotes stood out:

“The recent headlines regarding pharma’s ties to funding patient advocacy organizations are largely misled—many of us receive support from competing brands, and this removes bias from the equation.”

“This is an election year—Politicians are pounding podiums and many are painting pharma as the bad guy. Leaders across your industry should be better at standing up for their companies, and us as advocates, too. We could all use the help of PR professionals to transform the conversation to more accurately reflect reality.”

—Andrew Schorr, Founder of Patient Power

“Patients are very savvy—especially when it comes to sniffing out a fraud on social media. If our advocacy groups were being unethically influenced by pharma, our patients would quickly sense it.”

“Cost and value are complicated topics—as patients and advocates who have received fair reimbursement for services from pharma, we’re in a precarious position in regards to defending drug prices publically. We really need your support in this conversation.”    

—Paul Gileno, President of U.S. Pain Foundation

About the Author:

Drew Beck has spent his entire career in healthcare — from direct patient care as an EMT in college to countless roles in pharma sales and global marketing for leading life science companies including Eli Lilly & Co. and GlaxoSmithKline. He is currently a leader on the Syneos Health Insights & Innovation team, a group charged with leveraging deep expertise in virtual collaboration, behavioral science, trends-based-innovation, custom research and global marketing insights.